NLS Pharmaceutics AG
NLSP
$1.47
-$0.053-3.48%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 57.36% | 41.29% | 26.21% | 14.90% | 3.23% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 3.57% | 7.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | 0.00% | -- |
| Total Other Non-Cash Items | -71.17% | -73.21% | -75.37% | 27.63% | 4,179.65% |
| Change in Net Operating Assets | 161.86% | 82.74% | 38.42% | -32.82% | -70.43% |
| Cash from Operations | 71.00% | 50.34% | 30.22% | 13.28% | -4.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 6.78% | 6.78% | 6.78% | 106.78% | -- |
| Total Debt Repaid | 45.03% | 81.60% | -- | 66.38% | -1.32% |
| Issuance of Common Stock | -81.09% | -91.66% | -- | -50.46% | 32.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -42.80% | 167.29% |
| Cash from Financing | -79.58% | -85.73% | -90.61% | -37.06% | 93.49% |
| Foreign Exchange rate Adjustments | 150.00% | 150.00% | -- | -300.00% | -300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -469.72% | -339.87% | -328.90% | -249.14% | 105.18% |